413 related articles for article (PubMed ID: 20218747)
21. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.
Schechter BA; Parekh JG; Trattler W
J Ocul Pharmacol Ther; 2015 Mar; 31(2):114-21. PubMed ID: 25409447
[TBL] [Abstract][Full Text] [Related]
22. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
23. Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis.
Keating GM
Drugs; 2011 Jan; 71(1):89-99. PubMed ID: 21175242
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
Baiza-Durán L; Olvera-Montaño O; Mercado-Sesma AR; Oregon-Miranda AA; Lizárraga-Corona A; Ochoa-Tabares JC; Pérez-Balbuena AL; Montoya-Sánchez IM; Saucedo-Rodríguez LR; Mora-González A; Gómez-Bastar PA; Villanueva-Najera MA; Sandoval-Delgadillo LI; González-Lomelí M; Páez-Garza JH; Orozco-Carroll M; Casillas-Magallanes M
J Ocul Pharmacol Ther; 2018 Apr; 34(3):250-255. PubMed ID: 29624493
[TBL] [Abstract][Full Text] [Related]
25. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Silver LH; Woodside AM; Montgomery DB
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
[TBL] [Abstract][Full Text] [Related]
26. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
Granet DB; Dorfman M; Stroman D; Cockrum P
J Pediatr Ophthalmol Strabismus; 2008; 45(6):340-9. PubMed ID: 19043945
[TBL] [Abstract][Full Text] [Related]
27. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Parekh JG; Newsom TH; Nielsen S
J Cataract Refract Surg; 2012 Oct; 38(10):1864-7. PubMed ID: 22999608
[No Abstract] [Full Text] [Related]
28. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
29. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
30. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections.
Silverstein BE; Morris TW; Gearinger LS; Decory HH; Comstock TL
Clin Ophthalmol; 2012; 6():1987-96. PubMed ID: 23233796
[TBL] [Abstract][Full Text] [Related]
31. Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older.
Heller W; Cruz M; Bhagat YR; De Leon JM; Felix C; Villanueva L; Hollander DA; Jensen H
J Ocul Pharmacol Ther; 2014 Dec; 30(10):815-22. PubMed ID: 25244402
[TBL] [Abstract][Full Text] [Related]
32. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
33. Besifloxacin in the management of bacterial infections of the ocular surface.
Deschênes J; Blondeau J
Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217
[TBL] [Abstract][Full Text] [Related]
34. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients.
Yoshida J; Kim A; Pratzer KA; Stark WJ
J Cataract Refract Surg; 2010 Sep; 36(9):1499-502. PubMed ID: 20692561
[TBL] [Abstract][Full Text] [Related]
35. Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Majmudar PA; Clinch TE
Cornea; 2014 May; 33(5):457-62. PubMed ID: 24637269
[TBL] [Abstract][Full Text] [Related]
36. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
Lichtenstein SJ; De Leon L; Heller W; Marshall B; Cupp G; Foster K; McLean C; Levy S; Stroman DW
J Pediatr Ophthalmol Strabismus; 2012; 49(2):88-97. PubMed ID: 22074357
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes.
Morris TW; Gearinger LS; Usner DW; Paterno MR; Decory HH; Comstock TL; Haas W
Clin Ophthalmol; 2011; 5():1359-67. PubMed ID: 22034555
[TBL] [Abstract][Full Text] [Related]
38. A single-blinded randomized clinical trial comparing polymyxin B-trimethoprim and moxifloxacin for treatment of acute conjunctivitis in children.
Williams L; Malhotra Y; Murante B; Laverty S; Cook S; Topa D; Hardy D; Wang H; Gigliotti F
J Pediatr; 2013 Apr; 162(4):857-61. PubMed ID: 23092529
[TBL] [Abstract][Full Text] [Related]
39. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
40. Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
Med Lett Drugs Ther; 2004 Mar; 46(1179):25-7. PubMed ID: 15057188
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]